After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ultragenyx Pharmaceutical Inc is $3.30B. A total of 0.62 million shares were traded on the day, compared to an average of 1.46M shares.
In the most recent transaction, Horn Howard sold 3,081 shares of RARE for 36.38 per share on Dec 10 ’25. After the transaction, the Chief Financial Officer now owns 95,146 company shares. In a previous transaction on Dec 10 ’25, HOWARD HORN bought 3,081 shares at 36.38 per share.
Among the insiders who sold shares, Horn Howard disposed of 7,942 shares on Oct 13 ’25 at a per-share price of $31.51. This resulted in the Chief Financial Officer holding 98,227 shares of RARE after the transaction. In another insider transaction, Huizenga Theodore Alan sold 64 shares at $29.17 per share on Sep 18 ’25. Company shares held by the SVP, Chief Accounting Officer now total 50,242.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RARE has a high of $46.50 and a low of $25.81.
As of this writing, RARE has an earnings estimate of -$1.23 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.8 per share and a lower estimate of -$1.87. The company reported an EPS of -$1.39 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $0.10, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.77.
